by clicking the arrows at the side of the page, or by using the toolbar.
by clicking anywhere on the page.
by dragging the page around when zoomed in.
by clicking anywhere on the page when zoomed in.
web sites or send emails by clicking on hyperlinks.
Bio Technology : October 2009
Volume 19 • Number 3 • October 2009 Australasian BioTechnology 75 AusBioPEOPLE Sector on the move Who is where? The biotechnology sector is characterised by upward of one thousand small to medium-sized companies, most of which are in their growth phase. Not surprising, staff and board members, junior and senior, move frequently around the sector. In addition, the new financial year heralded new- look boards for quite a few companies. From 1 June to the 31 August some of the moves include the following: NEURODISCOVERY: Harry Karelis was appointed as a director, representing major shareholder Biotech Capital, and Dr Tony Evans and Dr Iain Chessell resigned. ROCKEBY: Edwin Leith Boyd was appointed a director. BIOSIGNAL: Robert Vickery has resigned as company secretary and chief financial officer. Timothy Morrison was appointed as company secretary. EASTLAND MEDICAL SYSTEMS: Douglas Sims retired as a director and Michael Stewart was appointed as a non-executive director. SIENNA DIAGNOSTICS: Dr Ian Macreadie was appointed as chief scientific officer. TISSUE THERAPIES: Queensland Biocapital Funds chief executive officer, Dr Cherrell Hirst, was appointed a director. AVEXA: Lawrence Gozlan replaced Dr John Sime as a non-executive director. PROGEN: Progen appointed Stuart James as its chairman, and John Chiplin, Julie Cherrington, Gordon Schooley, Heng Hsin Tang, Joe Yeh-Chiao and Thomas Burt as non-executive directors. FERMISCAN: managing director, David Young, and chief financial officer, Greg West, resigned. Leon Carr was appointed to the board to fill the vacancy. SOLAGRAN: Dr Robert Payne resigned as a director and company secretary. Justyn Stedwell was appointed company secretary. ITL LTD: Sharon Winsale resigned as company secretary and chief financial officer, Greg Lewis, was appointed, but subsequently from both positions resigned. Chief executive officer, Brian Andrews was appointed as managing director. ROCKEBY: Kow Hin Fan was appointed a director and Edwin Leith Boyd resigned. BIODIEM: appointed Julie Phillips (formerly Julie Nutting) as chief executive officer. IMMURON: director and former chief executive officer, Dr Zeil Rosenberg. STIRLING PRODUCTS: announces its senior management team with managing director Peter Boonen. Commercialisa- tion and development to be managed from Canada, by group manager and chief operating officer Shane Patelakis; chief financial officer, Neil Ferguson; Dr Allen Bain as chief science officer; project co-ordinator, Dr Aldar Bourinbaiar; and principal investigator and lead clinical manager, Dr Galyna Kutsyna. Dr Hinner Köster and Hugo Hattingh were appointed directors of Stirling's South African joint venture. IMPEDIMED: announced the role of chief financial officer will be transferred to the group's San Diego facility after Phil Auckland was appointed to "a new Australian-based executive role and resigned" Kym Fletcher was appointed interim CFO. AGENIX: announced it will not renew chief executive officer Dr Stephen Phua's contract in January 2010. CIRCADIAN TECHNOLOGIES: Dr Errol Malta was appointed a non-executive director. ACTINOGEN: appointed chief financial officer Mark Killmier as company secretary, to replace David Zohar. CHEMGENEX: appointed Thomas Dezao as senior vice president and chief commercial Officer. NOVOGEN: Peter Simpson has resigned as a director. NEURODISCOVERY: founding director, John Hannaford, resigned. SELECT VACCINES: Robin Beaumont resigned as a director and chairman. PROBIOMICS: chief executive officer, Stuart Craig, resigned. ANTEO DIAGNOSTICS: Bruce Rathie has resigned as non-executive director. BIOPROSPECT: appointed Solagran employee Kamran Shamsi as a non-executive. BIOPHARMICA: company secretary Deborah Ambrosini was appointed as a director.